Cyclin G2 inhibitors belong to a specific chemical class of compounds that are designed to target and modulate the activity of cyclin G2, a regulatory protein involved in the cell cycle progression. Cyclin G2 is a key component of the cell cycle machinery and plays a crucial role in the regulation of cell division and proliferation. The inhibitors of this class are carefully designed molecules that are intended to interact with cyclin G2 and inhibit its function, thereby disrupting the cell cycle process. The mechanism of action of cyclin G2 inhibitors involves their ability to bind to cyclin G2 protein, either directly or through specific cellular pathways. By forming these interactions, cyclin G2 inhibitors can prevent the proper functioning of the cyclin G2 protein and subsequently disrupt the coordination of the cell cycle. This interference can lead to alterations in cell cycle progression, including delays or arrest at various stages of the cell division process.
The development of cyclin G2 inhibitors is a result of extensive research into understanding the intricate molecular mechanisms involved in cell cycle regulation. Scientists have worked diligently to identify and design small molecules or compounds that specifically target cyclin G2, with the aim of advancing our knowledge of cell biology and providing potential opportunities for further exploration in a research context. Overall, cyclin G2 inhibitors represent a fascinating area of chemical research with implications for fundamental biological understanding. Their specific interactions with cyclin G2 and modulation of the cell cycle process offer promise for potential future investigations in cell biology and further contribute to the scientific community's comprehension of cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
While Purvalanol A is a broad-spectrum cyclin-dependent kinase (CDK) inhibitor, it has been shown to inhibit Cyclin G2-associated CDKs. | ||||||
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $66.00 $163.00 $326.00 | 37 | |
This inhibitor primarily targets CDK1 and CDK2, but it may also influence Cyclin G2-mediated cell cycle regulation. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
An inhibitor with selectivity against CDK2, CDK5, and CDKIt may have effects on Cyclin G2 as well. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
This inhibitor targets multiple CDKs, including CDK1, CDK2, CDK4, CDK5, and CDK9, and it may indirectly impact Cyclin | ||||||
CVT-313 | 199986-75-9 | sc-221445 sc-221445A sc-221445B | 1 mg 5 mg 50 mg | $104.00 $416.00 $2601.00 | 17 | |
Known to inhibit CDK2 and CDK5, but its effect on Cyclin G2 has not been extensively studied. | ||||||